机构：[1]Hunan University of Chinese Medicine, Changsha, China[2]Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China[3]Guangdong Provincial People’s Hospital Zhuhai Hospital (Zhuhai Golden Bay Center Hospital), Zhuhai, China[4]The First Affiliated Hospital of Hunan Traditional Chinese Medical College, Zhuzhou, China[5]China Pharmaceutical University, Nanjing, China[6]Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China[7]International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China[8]Toxicology Counseling Center of Hunan Province (TCCH), Changsha, China
BackgroundHepatic cancer is a common cancer in clinical practice. Current drug therapies for this condition include targeted therapy, chemotherapy, and immunotherapy. Tumor lysis syndrome (TLS) is the most serious complication of oncology treatment. According to the literature, several cases reported TLS occurred with targeted therapies for hepatic cancer.MethodsReporting odds ratio and information component were used to measure the disproportionate signals for TLS associated with targeted therapies, using data from the FDA's Adverse Event Reporting System (FAERS). A stepwise sensitivity analysis was conducted to test the robustness of signals. Time-to-onset analysis was used to describe the latency of TLS events associated with targeted therapies. The Bradford Hill criteria were used to perform a global assessment of the evidence.ResultsSorafenib, lenvatinib, cabozantinib, and bevacizumab showed higher disproportionate signals for TLS than chemotherapy. The median number of days to TLS occurrence after drug therapy was 5.5, 6.5, and 6.5 days for sorafenib, lenvatinib, and bevacizumab, respectively.ConclusionsThere is a significant association between tumor lysis syndrome and targeted therapies for hepatic carcinoma, with particularly strong signals for sorafenib and lenvatinib. Clinicians should be aware of the potential for tumor lysis syndrome in targeted therapies for hepatic carcinoma.
基金：
Natural Science Foundation of Hunan Province [2023JJ60351]; National Natural Science Foundation of China [82274033]
第一作者机构：[1]Hunan University of Chinese Medicine, Changsha, China
共同第一作者：
通讯作者：
通讯机构：[2]Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China[7]International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, China[8]Toxicology Counseling Center of Hunan Province (TCCH), Changsha, China[*1]The First Affiliated Hospital of Hunan Traditional Chinese Medical College, Zhuzhou 410016, China[*2]Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China
推荐引用方式(GB/T 7714)：
Liu Ling,Zhang Chengyi,Liu Huihui,et al.Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system[J].EXPERT OPINION ON DRUG SAFETY.2024,doi:10.1080/14740338.2024.2312147.
APA：
Liu, Ling,Zhang, Chengyi,Liu, Huihui,Luo, Huan,Cao, Rong...&Jiang, Zhichao.(2024).Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system.EXPERT OPINION ON DRUG SAFETY,,
MLA：
Liu, Ling,et al."Reporting of tumor lysis syndrome with targeted therapy for hepatic cancer in the FDA adverse events reporting system".EXPERT OPINION ON DRUG SAFETY .(2024)
：